Ticker brief
SYRE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
20
authors 14d
11
crowd 14d
-1.8σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.30 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 5 | +0.52 |
| @SteveDJacobs | C | -1.22 | 4 | +0.19 |
| @Biotech2k1 | A | +1.02 | 2 | -0.20 |
| @semodough | C | -3.01 | 2 | -0.20 |
| @BPharmCatalyst | C | · | 1 | -0.35 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @Briefingcom | B | +0.50 | 1 | -0.60 |
| @fundmyfund | B | -1.58 | 1 | -0.50 |
| @fwpharma | B | +0.98 | 1 | -0.30 |
| @Quantumup1 | C | · | 1 | +0.40 |
| @Caesar_ish | C | -0.44 | 1 | -0.15 |
Recent signals20of 20 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Caesar_ish | -0.15 | Reports a major SPY072 development-plan revision and continues watching for an IBD catalyst. | · | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | +0.65 | Frames SYRE as a broad platform positioned to compete with major immunology companies and exceed peer disease breadth. | · | tweet ↗ |
| 2026-08-28 | @Quantumup1 | +0.40 | Guggenheim reiterates SYRE as a Buy and Top Pick with a $130 target. | · | tweet ↗ |
| 2026-08-26 | @fwpharma | -0.30 | Reports Spyre's anti-TL1A showed activity but fell short in a Phase II rheumatoid-arthritis study. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.00 | Concludes Abivax is undervalued after reading reports on Spyre. | · | tweet ↗ |
| 2026-08-26 | @fundmyfund | -0.50 | Reports SYRE fell 12% on trial-related news. | · | tweet ↗ |
| 2026-08-26 | @Briefingcom | -0.60 | SYRE's rheumatoid-arthritis sub-study effect did not meet its target. | · | tweet ↗ |
| 2026-08-26 | @semodough | -0.40 | Reports LifeSci cutting SYRE's price target to $116 from $129 while outlining trial timelines. | · | tweet ↗ |
| 2026-08-26 | @Biotech2k1 | -0.55 | Says SYRE's bubbly valuation has moved ahead of its supporting data. | · | tweet ↗ |
| 2026-08-25 | @OzmosiHealth | +0.00 | Spyre announced topline results from a rheumatoid-arthritis sub-study of its Phase 2 SKYWAY trial. | · | tweet ↗ |
| 2026-08-25 | @BPharmCatalyst | -0.35 | Phase 2 data met significance but missed internal monotherapy thresholds, prompting a pipeline pivot. | · | tweet ↗ |
| 2026-08-25 | @Biotech2k1 | +0.15 | Names several companies as examples, but the parent context is missing. | · | tweet ↗ |
| 2026-08-23 | @bioinvestor24 | +0.45 | Speculates Novartis could pursue Syre as a needed immunology acquisition and eventually resemble BMY. | · | tweet ↗ |
| 2026-08-23 | @bioinvestor24 | +0.55 | Calls the three Paragon spinouts the best immunology companies and cites their gains. | · | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | +0.60 | Reports a third party's large SYRE stake, VKTX sale, RYTM addition and MRNA short. | · | tweet ↗ |
| 2026-08-18 | @SteveDJacobs | -0.10 | Wednesday watchlist is broadly cautious because several names are below their 200-day moving averages. | · | tweet ↗ |
| 2026-08-18 | @SteveDJacobs | +0.45 | Uses SYRE to illustrate a systematic pilot-position and scale-in approach after a chart buy/add signal. | · | tweet ↗ |
| 2026-08-18 | @SteveDJacobs | +0.25 | Lists stocks closing green and identified by multiple relative-strength and growth scanners. | · | tweet ↗ |
| 2026-08-16 | @bioinvestor24 | +0.35 | Questions KYMR's valuation, differentiation and development timeline while comparing peers and FOMO. | · | tweet ↗ |
| 2026-08-16 | @SteveDJacobs | +0.15 | Publishes a Qullamaggie technical scan; output is capped at the first six stocks. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.